Cronos Group Inc.
NASDAQ:CRONDrug Manufacturers - Specialty & Generic
-$0.02 today
- Market cap
- $1.16B
- Beta
- 1.25
- P/E (TTM)
- -488.3
- EPS (TTM)
- -$0.01
Volume 1.13M
Average 1.51M
CRON Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cronos Group Inc.NASDAQ: CRON
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables dips below year-ago levels
Q1 FY2026 accounts payables of $1.19M (cash outflow) fell 27.3% year over year, behind the +125.3% change in trailing-twelve-month accounts payables.
Context
- Accounts payables amounted to 0.8% of revenue in FY2025, down 5.6 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -27.3% toward the trailing-twelve-month pace of +125.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- +115.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | +115.1% |
| FY2024 | 2024-12-31 | (7.45M) | -863.6% |
| FY2023 | 2023-12-31 | (773K) | +10.4% |
| FY2022 | 2022-12-31 | (863K) | +46.0% |
| FY2021 | 2021-12-31 | (1.6M) | — |
Accounts Payables vs competitors
How CRON compares with its peers on the latest reported figures
- CRON's LTM Mar 2026 accounts payables of $1.6M is the 10th largest of the 11 companies compared; the peer median is $3.27M.
- Its year-over-year change of +125.3% is the 5th highest of 11, against a peer median of -53.3%.
- Accounts payables amounts to 0.8% of revenue for CRON, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $37.94M | +15.0% | +57.8% | 18.5% | |
| LTM Aug 2026 | $25.05M | +537.3% | — | 3.6% | |
| LTM Mar 2026 | $23.4M | +2500.0% | — | 2.2% | |
| LTM Mar 2026 | $12.56M | -121.6% | +83.7% | 1.7% | |
| LTM Mar 2026 | $11.03M | -313.0% | — | 1.4% | |
| LTM Mar 2026 | $9M | -171.8% | — | 1.2% | |
BBOTBridgeBio Oncology Therapeutics Inc. | LTM Mar 2026 | $6.22M | +5837.6% | — | — |
| LTM Jun 2026 | $6.13M | -229.5% | +0.3% | 5.8% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $4.34M | +345.5% | — | 21.7% |
| LTM Mar 2026 | $1.6M | +125.3% | — | 0.8% | |
| LTM Mar 2026 | $407.64K | -186.3% | — | 0.5% | |
| Peer median (excluding CRON) | $3.27M | -53.3% | +57.8% | 2.2% | |
Competitors are the stored peer set for CRON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (397.2M) | (168.73M) | (74.55M) | 40.02M | (2.93M) |
| Depreciation & Amortization | 15.4M | 13.12M | 8.11M | 9.34M | 14.48M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 15.12M | 8.77M | 8.7M | 7.05M |
| Change in Working Capital | (4.84M) | 15.66M | (26.47M) | (311K) | (35.02M) |
| Accounts Receivables | (12.16M) | (8.55M) | (6.59M) | (917K) | (26.2M) |
| Inventory | 11.57M | (7.22M) | 7.4M | 5.28M | (10.58M) |
| Accounts Payables | (1.6M) | (863K) | (773K) | (7.45M) | 1.13M |
| Other Working Capital | (2.65M) | 32.29M | (26.51M) | 2.77M | 636.96K |
| Other Non-Cash Items | 222.88M | 35.89M | 41.31M | (38.9M) | 42.73M |
| Operating Cash Flow | (153.62M) | (88.95M) | (42.84M) | 18.84M | 26.32M |
| Capital Expenditures | (12.26M) | (5.03M) | (3.42M) | (13.15M) | (26.17M) |
| Acquisitions (Net) | 0 | 0 | 0 | 5.71M | 2.9M |
| Purchases of Investments | (230M) | (271.38M) | (608.25M) | (8.34M) | (59.44M) |
| Sales of Investments | 215.3M | 268.87M | 532.84M | 181.9M | 5.15M |
| Other Investing Activities | (3.06M) | 4.12M | 18.42M | 8.41M | 0 |
| Investing Cash Flow | (28.9M) | (1.84M) | (59.5M) | 175.15M | (77.9M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (9.91M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (10.34M) |
| Financing Cash Flow | (13.44M) | (2.9M) | (1.03M) | (1.23M) | (20.25M) |
| Effect of Forex Changes | 4.91M | (28.64M) | 8.01M | (3.25M) | 3.89M |
| Net Change in Cash | (191.05M) | (122.33M) | (95.35M) | 189.51M | (67.94M) |
| Free Cash Flow | (165.88M) | (93.98M) | (46.26M) | 5.69M | 151.61K |
Cronos Group Inc.
NASDAQ:CRON
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.